RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 2/Phase 3

Registered title, quoted from ClinicalTrials.gov

A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC

An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Sun Yat-sen Memorial Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorSun Yat-sen Memorial Hospital中山大学孙逸仙纪念医院GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT04803539, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 80 years; sex: women only

    Registered eligibility fields

  2. Stage II - III primary triple negative breast cancer patients(TNBC), TNBC is defined as ER <=1%, PR <=1%;HER2 receptor IHC=1, or IHC=2 and FISH negative.

    Inclusion criterion 2

    Patient with distant metastases of breast cancer beyond regional lymph nodes (stage IV according to AJCC 8th edition)

    Exclusion criterion 3

  3. Patient has previously received any PD1/PDL1 blockage treatment

    Exclusion criterion 1

    Patient has a concurrent invasive malignancy or a prior invasive malignancy whose treatment was completed within 3 years before randomization

    Exclusion criterion 5

  4. ECOG 0-2

    Inclusion criterion 4

  5. Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or breast-feed during the trial

    Exclusion criterion 2

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT04803539, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Patient is ≥ 18 years-old at the time of consent to participate this trial
  • Stage II - III primary triple negative breast cancer patients(TNBC), TNBC is defined as ER <=1%, PR <=1%;HER2 receptor IHC=1, or IHC=2 and FISH negative.
  • positive ctDNA after curative surgery and/or adjuvant chemotherapy
  • ECOG 0-2
  • If indicated, patient agree to receive adjuvant radiotherapy according to the institutional guidelines
  • Patient receives adjuvant chemotherapy according to the NCCN guidelines
  • Patient has available tumor tissue from the surgical specimen for next generation sequencing(NCS)
  • Patient agrees to give blood samples for ctDNA tests every 3 months in 5 years

Exclusion Criteria:

  • Patient has previously received any PD1/PDL1 blockage treatment
  • Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or breast-feed during the trial
  • Patient with distant metastases of breast cancer beyond regional lymph nodes (stage IV according to AJCC 8th edition)
  • Patient participates another interventional clinical trial
  • Patient has a concurrent invasive malignancy or a prior invasive malignancy whose treatment was completed within 3 years before randomization
  • Patient with autoimmune disease preventing the use of camrelizumab
  • Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the Investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical trial or compromise compliance with the protocol

Quoted from ClinicalTrials.gov, NCT04803539, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT04803539, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT04803539